Found: 21
Select item for more details and to access through your institution.
Strongly Consistent Steady-State Derivative Estimates.
- Published in:
- Probability in the Engineering & Informational Sciences, 1991, v. 5, n. 4, p. 391, doi. 10.1017/S0269964800002199
- By:
- Publication type:
- Article
Spatiotemporal measurement of surfactant distribution on gravity–capillary waves.
- Published in:
- Journal of Fluid Mechanics, 2015, v. 777, p. 523, doi. 10.1017/jfm.2015.352
- By:
- Publication type:
- Article
Isocitrate dehydrogenase inhibitor‐driven differentiation may resemble secondary graft failure in post‐allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 5, p. 927, doi. 10.1111/bjh.17573
- By:
- Publication type:
- Article
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/ MDS.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 3, p. 427, doi. 10.1111/bjh.14244
- By:
- Publication type:
- Article
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 6, p. 796, doi. 10.1111/bjh.13214
- By:
- Publication type:
- Article
Secondary‐type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. E462, doi. 10.1002/ajh.26730
- By:
- Publication type:
- Article
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
- Published in:
- Drugs, 2016, v. 76, n. 13, p. 1245, doi. 10.1007/s40265-016-0614-z
- By:
- Publication type:
- Article
Optimizing Personalized Bone Marrow Testing Using an Evidence-Based, Interdisciplinary Team Approach.
- Published in:
- American Journal of Clinical Pathology, 2013, v. 140, n. 5, p. 643, doi. 10.1309/AJCP8CKE9NEINQFL
- By:
- Publication type:
- Article
Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S208, doi. 10.1016/j.clml.2018.07.064
- By:
- Publication type:
- Article
RADIUS-X: An Expanded Treatment Protocol for Midostaurin in Combination with Standard Chemotherapy in Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S202, doi. 10.1016/j.clml.2018.07.053
- By:
- Publication type:
- Article
Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-Naïve Elderly Patients with Acute Myeloid Leukemia (AML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S202, doi. 10.1016/j.clml.2018.07.052
- By:
- Publication type:
- Article
Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S286, doi. 10.1016/j.clml.2017.07.071
- By:
- Publication type:
- Article
Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S287, doi. 10.1016/j.clml.2017.07.073
- By:
- Publication type:
- Article
Stochastic modeling and the theory of queues, by R. W. WOE, Rentice Hall, Engle- wood Cliffs, NJ, 1989, 556 pp.
- Published in:
- Networks, 1991, v. 21, n. 3, p. 371, doi. 10.1002/net.3230210309
- By:
- Publication type:
- Article
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00677-7
- By:
- Publication type:
- Article
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 9, p. 1006, doi. 10.1002/ajh.25859
- By:
- Publication type:
- Article
Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 7, p. E134, doi. 10.1002/ajh.24009
- By:
- Publication type:
- Article
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Working for peace.
- Published in:
- Harvard International Review, 1996, v. 18, n. 4, p. 34
- By:
- Publication type:
- Article
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 23, p. 4421, doi. 10.1002/cncr.33828
- By:
- Publication type:
- Article
Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.
- Published in:
- BMC Genomics, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s12864-015-1929-y
- By:
- Publication type:
- Article